HEREMOS
Stand n.36

HEREMOS

Boosting Clinical Trials with RAW Data and AI

Start-up of Regione Lazio

Regione Lazio

Start-up

www.heremos.com

Description

HEREMOS provides wearable medical devices for real-time RAW physiological data collection and processing. Utilizing AI, it extracts vitals, clinical indicators, and biomarkers. The system features a sensorized body area network (BAN) that monitors patients' physiological activities via a wrist unit and a chest patch, equipped also with ambient sensors. High-frequency, high-quality data collection feeds into a Big Data-optimized database, enabling real-time and historical analysis to support personalized studies and risk assessment. Ideal for remote patient monitoring and enhancing clinical trial efficiency, HEREMOS targets pharmaceutical companies, CROs, pharmacies, and hospitals. HEREMOS AI algorithm for nociceptive pain detection is currently under clinical validation.

Our products

Specializing in RAW data collection/processing with wearable medical devices, we use AI to extract biomarkers.

Specializing in RAW data collection/processing with wearable medical devices, we use AI to extract biomarkers.

HEREMOS delivers cutting-edge wearable devices for instant RAW data gathering and analysis from physiological signals. Utilizing proprietary algorithms and AI, we extract vitals and biomarkers, offering a comprehensive view of patient well-being. Our suite includes a sensor-integrated body area network for patient remote monitoring, featuring a wrist smart band and a chest smart patch with a multi-lead ECG for advanced cardiac insights. HEREMOS sensors capture data at unparalleled rates and precision, feeding into a Big Data-ready system that supports both live and historic data analysis. We serve entities like pharma, CROs, and healthcare providers focused on boosting trial efficiency and enhancing patient outcomes, adapting to the shift towards remote and patient-focused clinical research. The capability to archive RAW data facilitates multiple longitudinal studies on the same cohort, unveiling novel potential applications for the drug under investigation.